Araris will use its linker technology to generate multi-warhead ADCs for “undisclosed targets” provided by Chugai.

TORONTO, ON / ACCESSWIRE / January 7, 2025 / ProteinQure, a leader in computational peptide design, is proud to announce the ...

peptide drug conjugates (PDC) and multi-functional peptide conjugates (MPC) across an extensive global network of discovery and development partners. PeptiDream is headquartered in Kawasaki ...

CBX-12 is under clinical development by Cybrexa and currently in Phase II for Gallbladder Cancer. According to GlobalData, Phase II drugs for Gallbladder Cancer have a 32% phase transition success ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to GSK5764227 (GSK’227) for the treatment of adult patients with relapsed or refractory (R/R) osteosarcoma who have ...

Ke Hou generated a compound that prevents tau aggregation in the murine brain, but the potential Alzheimer’s disease therapy ...

providing unrivalled access to 30+ speakers discussing innovation and development in bispecific-drug conjugates, antibody-oligonucleotide conjugates, peptide-drug conjugates plus many other novel ...

INR:2922. crypto casino without kyc East Sunshine Pharmaceutical to win 1.5 billion antithrombotic drug Precision-guided myeloma drug! Melflufen, the fi ...

R&D Daily丨DaShi Pharmaceutical's first IND application for a new antibody drug targeting NGF was accepted ChK1 inhibitor!

GSK5764227 (HS-20093) is a novel antibody-drug conjugate composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload.

TORONTO, ON / ACCESSWIRE / January 7, 2025 / ProteinQure, a leader in computational peptide design, is proud to announce the addition of two distinguished leaders to its team. Dr. Dave Garman has been ...